Investing in early-stage stem cell therapy developers

“Providing a future, healthy, and competitive commercial cell therapy landscape depends on young companies having early access to sufficient capital to advance new transformational and complementary cell therapies.”

Authors

Institutions

Publication Details

Journal
Cell and Gene Therapy Insights
Published
2025-02-21
DOI
https://doi.org/10.18609/cgti.2025.023
Primary Topic
Biomedical Ethics and Regulation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Investing in early-stage stem cell therapy developers

Kristian Tryggvason, Stijn Heessen
Cell and Gene Therapy Insights
Biomedical Ethics and Regulation
article

Investing in early-stage stem cell therapy developers

Kristian Tryggvason, Stijn Heessen
article en

Abstract

“Providing a future, healthy, and competitive commercial cell therapy landscape depends on young companies having early access to sufficient capital to advance new transformational and complementary cell therapies.”

Cell and Gene Therapy InsightsVol. 11(2)
Netherlands Enterprise Agency (NL), Modus Therapeutics (Sweden) (SE)
Openalex Percentile: Top 50%
Biomedical Ethics and Regulation
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Investing in early-stage stem cell therapy developers — Kristian Tryggvason, Stijn Heessen · Cell and Gene Therapy Insights (2025) | TGRS Research Map | TGRS